Table 4 Frequency of adverse events reported during the therapeutic efficacy monitoring in Uganda at all sites, 2018–2019
| Â | Artemether-lumefantrine, n (%) | Dihydroartemisinin-piperaquine, n (%) |
|---|---|---|
Adverse events | ||
 Cough | 119 (39.0) | 122 (42.8) |
 Acute watery diarrhea | 43 (14.1) | 33 (11.6) |
 Mild skin rash | 15 (4.9) | 14 (4.9) |
 Mild anemia (8.0–10.0 g/dl) | 16 (5.2) | 15 (5.3) |
Serious adverse events | ||
 Fracture | 1 (0.3) | 0 (0.0) |
 Severe malaria | 1 (0.3) | 0 (0.0) |